Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Quantitative evaluations of trials of calcimimetics found no effects on cardiovascular events and cardiovascular and all-cause mortality when compared with placebo. However, a recent randomized, controlled trial of etelcalcetide versus alfacalcidol showed that etelcalcetide effectively inhibited the progression of LVH in comparison to vitamin D in patients on haemodialysis after 1 year of treatment. Prior to that, oral calcimimetic treatment has already been shown to reduce left ventricular mass in patients on haemodialysis, whereas treatment with active vitamin D or mineralocorticoids was ineffective in patients with ESKD. SUMMARY: Data from a recent trial of etelcalcetide on LVH suggest that FGF23 may be a possible therapeutic target for cardiac risk reduction in patients on haemodialysis. If these findings are confirmed by further research, it might be speculated that a treatment shift from active vitamin D towards FGF23-lowering therapy may occur in patients on haemodialysis.
|
Authors | Katharina Dörr, Alexander Kainz, Rainer Oberbauer |
Journal | Current opinion in nephrology and hypertension
(Curr Opin Nephrol Hypertens)
Vol. 31
Issue 4
Pg. 339-343
(07 01 2022)
ISSN: 1473-6543 [Electronic] England |
PMID | 35703173
(Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. |
Chemical References |
- Calcimimetic Agents
- Peptides
- Vitamin D
- Fibroblast Growth Factors
- etelcalcetide hydrochloride
|
Topics |
- Calcimimetic Agents
(therapeutic use)
- Fibroblast Growth Factors
(metabolism)
- Humans
- Hypertrophy, Left Ventricular
(drug therapy, etiology, metabolism)
- Kidney Failure, Chronic
(drug therapy, therapy)
- Peptides
- Vitamin D
(therapeutic use)
|